课题基金 / 基金详情

RHDNASE USE IN CYSTIC FIBROSIS PATIENTS YOUNGER THAN 5 YEARS OF AGE

RHDNASE USE IN CYSTIC FIBROSIS PATIENTS YOUNGER THAN 5 YEARS OF AGE
RHDNA 酶在 5 岁以下囊性纤维化患者中的使用
批准号：
6113538
负责人：
SAMYA Z NASR
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6113538
关键词：
clinical research cystic fibrosis deoxyribonuclease I drug screening /evaluation human subject human therapy evaluation infant human (0-1 year) inhalation drug administration metabolism disorder chemotherapy pediatric pharmacology preschool child (1-5) recombinant proteins respiratory function

项目摘要

项目成果

SAMYA Z NASR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Accumulation of purulent, infected sputum in the airways of patients with cystic fibrosis(CF) obstructs airways and causes chronic, symptomatic infection(1). Sputum in CF is rich in leukocyte-derived extracellular DNA that greatly contributes to the abnormal viscoelasticity of sputum (2,3). Recombinant human DNase I (rhDNase), a copy of the native human enzyme responsible for hydolyzing extracellular DNA, dramatically alters the viscoelastic properties of CF sputum in vitro (4). Aerosol administration of rhDNase with a pneumatically driven hand-held nebulizer improves pulmonary function in CF patients within days of initiating therapy (5,6). Longer-term administration of rhDNase also reduces the need for parenteral antibiotic treatment of respiratory tract infections(7). The purpose of this investigation is to evaluate the usefulness of rhDNase in children who are younger than 5 years of age.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SAFETY & EFFICACY OF EURAND PEP IN PATIENTS W/ CYSTIC FIBROSIS AND EPI
STUDY OF ORAL THERACLECTM - TOTAL IN CYSTIC FIBROSIS SUBJECTS W EXOCRINE PANCREA
RHDNASE USE IN CYSTIC FIBROSIS PATIENTS YOUNGER THAN 5 YEARS OF AGE
THE USE OF DORNASE ALFA (RHDNASE) IN RSV BRONCHIOLITIS
海外基金